Vanoxerine is a multi-ion channel blocker. For this reason, it was developed as a therapy for atrial fibrillation. However, in Phase III trials, 11.5% of patients developed torsades de pointes. Using MEA and human iPSC-derived cardiomyocytes, it was possible to detect this cardiotoxic liability.

In this poster, we focus on:

• The use of MEA and human iPSC-derived cardiomyocytes to detect vanoxerine arrhythmias
• The time dependent effect of vanoxerine cardiotoxicity
• The ADME properties of vanoxerine which may impact on its cardiotoxic effect

Read our poster to learn more about our research!